Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | IBI363 |
Indication/Tumor Type | colorectal cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | colorectal cancer | predicted - sensitive | IBI363 | Phase I | Actionable | In a Phase I trial, IBI363 treatment demonstrated safety in patients with advanced or metastatic CD274 (PD-L1)-positive (CPS>=1) colorectal cancer who had failed on or were intolerant to standard therapy (n=13) and resulted in an objective response rate of 30.8% and disease control rate of 76.9% (J Clin Oncol 42, 2024 (suppl 16; abstr 2504); NCT05460767). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study. | Full reference... |